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Abstract. Biomedical research has improved during the 
last decade in Catalonia, which is currently a well-recog-
nized international biomedical scientific hub. The policy 
of head-hunting and attraction of talent fostered by the 
Catalan Government through the ICREA Professorship ini-
tiative has been successful. In 2006, I was appointed as 
ICREA Professor and started a research group in Transla-
tional research in liver oncology at IDIBAPS-Hospital Clínic 
in Barcelona. This appointment was possible due to a sui-
table environment in this institution, both regarding liver 
and translational medical research. This article summarizes 
some of the major advancements in translational medicine, 
liver research and translational hepatic oncology achieved 
during the last decade. 
Resum. La recerca biomèdica ha millorat notablement 
a Catalunya durant la darrera dècada de tal manera que 
el nostre país es considera un pol de recerca internacio-
nalment reconegut. Les polítiques endegades pel Govern 
de la Generalitat amb la creació del programa ICREA per a 
l’atracció de talent internacional han estat molt exitoses. 
En el meu cas, vaig tornar l’any 2006 de Nova York per orga-
nitzar un grup de recerca translacional en oncologia hepà-
tica al IDIBAPS-Hospital Clínic de Barcelona. Els avenços del 
nostre grup han estat possibles atès l’entorn científic que 
ofereix la institució pel que fa a recerca en malalties hepà-
tiques i en recerca translacional. El present article analitza 
alguns dels avenços en recerca translacional, recerca hepà-
tica i recerca translacional en oncologia hepàtica assolits al 
nostre país en la darrera dècada. 
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Translational medicine in Catalonia 
Translational medicine has achieved major goals during 
the last decade in Catalonia. We understand translational 
medicine as the branch of the biomedical field aimed to 
translate discoveries from basic research to the clinical se-
tting in order to benefit patients�. Originally, the concept 
of translational medicine was captured by the motto from 
bench to bedside, but I rather prefer to describe it as from 
the patient to the lab and back to the patient�. In most ins-
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tances, translational medicine equals to the modern clini-
cal research. In order to put this concept in context in Ca-
talonia, we need to take into account the following facts: 
a) Advancements produced in translational medicine 
represent, in my view, the most substantial and critical re-
search produced in biomedical centers in Catalonia, parti-
cularly by those centers associated with clinical hospitals, 
such as IDIBAPS (associated to Hospital Clínic of Barcelona), 
IDIBELL (associated to Hospital Bellvitge) and VHIR/ VHIO 
(associated to Hospital Vall d’Hebrón).
b) Recent data from the Catalan Government – reported 
in Science on Sept 29th,2017- between 2007 and 2015 Ca-
talonia has obtained 210 European Research Council (ERC) 
projects, with a total of 334M€ of funding. Some awarded 
projects are substantially translational in nature. 
c) Most of the so called Top 1% cited investigators 
worldwide working in Catalan institutions are conducting 
translational research in medicine. 
d) At least 3 Universities in Barcelona are offering stu-
dies in biomedical translational research. Among those, I 
am directing the Official Master in Translational Medicine, 
in the Faculty of Medicine, University of Barcelona. 
To further understand the depth of the achievements 
in translational medicine in our country, I am summarizing 
some of the ones that have been generated in my own ins-
titution, IDIBAPS-Hospital Clínic. 
a) Autoimmune encephalitis: Discovery of this new en-
tity -autoimmune encephalitis- and characterization of the 
NMDA receptor as the target of the immune system. This 
advancement has re-defined the molecular basis of some 
mental disorders, thus providing the rationale for a novel 
therapeutic approach�. 
b) Chronic lymphocytic leukemia (CLL): Novel classifi-
cation of CLL and discovery of the landscape of oncogenic 
mutations as potential targets for therapies�. 
c) Cancer of unknown origin: This entity is causing 
thousands of deaths worldwide. A recent study from IDIBE-
LL/IDIBAPS demonstrates that by exploring the methylome 
of the neoplastic cells it is possible to identify the primary 
origin of the neoplasm and optimize the treatment�. 
d) Alzheimer disease: Identification of amyloid-related 
biomarkers in the asymptomatic phase of Alzheimer’s di-
sease. This discovery paves the path towards primary pre-
vention of this devastating disease�. 
e) Bipolar disorder: By genome-wide analysis the au-
thors identified a DNA polymorphism able to predict res-
ponse to lithium for prevention of recurrence of bipolar 
disorder�.
Liver research at IDIBAPS-Hospital 
Clínic
The Liver Unit at Hospital Clínic-IDIBAPS is one of the 
3-4 international groups with a higher impact in advancing 
the understanding of the pathogenesis and treatment of li-
ver diseases during the last decades. This Unit was founded 
and led by Dr Joan Rodés, a giant in the world of Hepatolo-
gy. He was also founder of the European Association for the 
Study of the Liver (EASL) and Editor-in-chief of Journal of 
Hepatology. His outstanding scientific production – h index 
of 128- was acknowledged with several national and inter-
national awards. He had the vision in 1970-80 to organize 
the research in liver disease according to specific areas (as-
cites, portal hypertension, hepatitis, liver cancer and trans-
plant), assigning the leadership of each one to different 
faculties. An overview of the main contributions has been 
reported elsewhere�·�, and are summarized as follows: 
a) Staging and treatment of hepatocellular carcinoma 
(HCC): The proposal of the Barcelona-Clínic system (BCLC) 
for staging and treatment allocation��·��, has been adopted 
by European and US clinical practice guidelines of mana-
gement of HCC. This group has also provided the evidence 
for establishing chemoembolization as standard of care in 
intermediate HCC��, and led the international randomized 
trials supporting the use of sorafenib�� and regorafenib�� in 
first and second line treatments in advanced cases.
b) Pathogenesis and treatment of ascites: Characteri-
zation of the mechanisms involved in the development of 
liver-related complications, such as ascites��. In addition, 
the authors led several studied supporting the use of albu-
min infusion to prevent hepato-renal syndrome after large 
volume paracentesis�� and to improve survival of sponta-
neous bacterial peritonitis episodes��.
c) Treatment of portal hypertension: The group des-
cribed the pathofisiological mechanisms of portal hyper-
tension and the efficacy of pharmacological�� and non-phar-
macological therapeutic approaches��. 
d) Treatment of hepatitis C infection: The treatment 
of hepatitis C infection has revolutionized the field during 
the last 5 years. Nowadays, up to 90% of patients achieve 
sustained virological responses with the new drug antiviral 
treatments. The group has contributed to the understan-
ding and management of this infection in the context of 
chronic liver disease�� and after liver transplantation��. 
Other important achievements have been reported in 
the areas of liver transplantation and cholestatic disorders.
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Translational research in liver 
oncology 
In 2006, and taking advantage of the outstanding re-
search environment in the setting of the Liver Unit and the 
BCLC group, I created the group of translational research 
in liver oncology at the IDIBAPS- Hospital Clínic. This occu-
rred after spending 3 years at the Mount Sinai School of 
Medicine in Nova York, were I created the Liver Cancer Pro-
gram. Thus, after my return to Europe I retained the posi-
tion of Director of this program in NYC, which is currently 
the only NCI recognized liver cancer program in the US. 
As a result of these two outstanding positions, our group 
has been able to produce more than 200 research articles 
in peer-reviewed journals (mean impact factor/article: 18 
points).  This research has been supported by competitive 
(including EU and NIH grants) and non-competitive funding 
of around 20M€. I can proudly say that I have been able to 
mentor 35 physicians and scientists interested in transla-
tional research in liver oncology. As a result of all this effort 
we have made the following contributions: 
a) Establishment of the molecular classification of 
HCC. We proposed a molecular classification of HCC after 
analyzing the genome of >1000 cases��·��. More recently, 
we complemented the information by providing the cha-
racterization of the immune class of HCC, which is expec-
ted to respond to checkpoint inhibitors, and the exclusion 
class, which is expected to be primary resistant to immune 
therapies��.
b) Characterization of oncogenes and signaling pa-
thways involved in the pathogenesis of HCC. As a result of 
several studies we defined that the main molecular aberra-
tions occurring in HCC are nowadays non actionable, and 
only around 30% could be potentially treated with effective 
drugs��·��. From a more clinical perspective, some early clini-
cal trials are currently ongoing based upon these discoveries.
c) Establishment of the molecular characterization 
of intrahepatic colangiocarcinoma (iCCA) and discovery 
of novel oncogenic drivers. We proposed a novel classifi-
cation of iCCA and discovered a novel oncogene resulting 
from a translocation leading to a fusion protein involving 
FGFR2��·��. These results have been translated in early clini-
cal trials. 
d) Involvement in the design of clinical practice gui-
delines for the management of HCC. I have participated in 
developing the Clinical Practice Guidelines of management 
of HCC supported by the EASL (2001, 2012 and 2018) and 
ESMO (2018).
After analyzing the research achievements described 
above in the area of translational medicine, liver research 
and translational liver oncology, it seems obvious to me 
that successful research is achieved by scientist with a uni-
que fingerprint: a) talented leadership and group, b) ade-
quate environment to facilitate conducting high-end re-
search, c) hard work capacity, this is a constant in all cases, 
and d) focus on a specific area. 
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